Medical News / From ASH Meeting 2019, Adding Daratumumab to Myeloma Treatment Reduces Risk of Progression, Death

Phase 3 trial results comparing relapsed or refractory multiple myeloma treatment with carfilzomib, dexamethasone and daratumumab, versus carfilzomib and dexamethasone, showed that adding daratumumab led to a 37% reduction in the risk of progression or death. Source: MDMag. By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization.

read more

MORE MEDICAL NEWS
Beaumont Health’s 29th Annual Cardiovascular Conference in Beaver Creek, CO, this February built on its own ... read more
The 29th Annual Beaumont Health Cardiovascular Conference, held in Beaver Creek, CO, provided cardiology investigators and ... read more
Despite the progress made in the fight against cardiovascular disease in recent decades, stroke and mitigating ... read more
There may soon be a cure for sickle cell disease. A team of investigators, led by Erica ... read more